COVID-19 associated mucormycosis: A Descriptive Multisite Study from India.
Diabetes Metab Syndr
; 15(6): 102322, 2021.
Article
in English
| MEDLINE | ID: covidwho-1482539
ABSTRACT
BACKGROUND AND AIMS:
Mucormycosis is an invasive fungal infection and carries a significant morbidity and mortality. A number of cases of mucormycosis have been reported in association with COVID-19. In this study, a consortium of clinicians from various parts of India studied clinical profile of COVID-19 associated mucormycosis (CAM) and this analysis is presented here.METHODS:
Investigators from multiple sites in India were involved in this study. Clinical details included the treatment and severity of COVID-19, associated morbidities, as well as the diagnosis, treatment and prognosis of mucormycosis. These data were collected using google spreadsheet at one centre. Descriptive analysis was done.RESULTS:
There were 115 patients with CAM. Importantly, all patients had received corticosteroids. Diabetes was present in 85.2% of patients and 13.9% of patients had newly detected diabetes. The most common site of involvement was rhino-orbital. Mortality occurred in 25 (21.7%) patients. On logistic regression analysis, CT scan-based score for severity of lung involvement was associated with mortality.CONCLUSION:
Universal administration of corticosteroids in our patients is notable. A large majority of patients had diabetes, while mortality was seen in â¼1/5th of patients, lower as compared to recently published data.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Adrenal Cortex Hormones
/
Diabetes Complications
/
COVID-19
/
Mucormycosis
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS